GleamWall
中文EN

GRAL GRAIL, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 1699031 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.5%
TTM net income YoY0.0%
TTM EPS YoY13.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-347.3%
Net margin-243.8%
FCF margin-187.3%
EBITDA margin-337.4%

Returns

ROE-17.3%
ROA-15.2%
ROIC (approx.)-20.1%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets10.1%
Debt / equity0.00x
Current ratio8.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue3.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$37.53M$44.69M$40.78M$43.60M$36.19M$35.54M$31.84M$38.25M
R&D expense$44.07M$47.43M$48.02M$46.90M$48.65M$46.63M$53.62M$48.33M
SG&A expense$40.74M$50.71M$42.77M$38.71M$37.41M$37.91M$45.07M$42.12M
Operating income-$144.62M-$173.78M-$135.76M-$124.41M-$125.29M-$158.85M-$153.61M-$136.94M
Pretax income-$137.32M-$166.71M-$127.52M-$116.52M-$118.72M-$152.86M-$146.41M-$126.99M
Income tax-$33.75M-$56.46M-$34.34M-$17.34M-$29.74M-$38.87M-$40.20M-$29.93M
Net income-$103.57M-$110.25M-$93.19M-$99.18M-$88.98M-$113.98M-$106.21M-$97.07M
EBITDA-$140.73M-$169.68M-$131.56M-$120.09M-$120.89M-$154.26M-$148.91M-$132.08M
EPS (basic)-2.21-2.56-2.29—-2.46-3.18-3.10—
EPS (diluted)-2.21-2.56-2.29—-2.46-3.18-3.10—
Weighted avg. shares (diluted)46.78M43.11M40.64M—36.12M35.79M34.31M—
Balance sheet
Cash & equivalents$28.98M$55.65M$69.34M$249.73M$126.89M$127.43M$133.90M$217.58M
Receivables$19.00M$19.76M$20.34M$18.30M$16.28M$16.31M$19.31M$20.31M
Current assets$842.80M$914.72M$877.35M$953.85M$589.38M$651.84M$727.65M$819.86M
PP&E, net$42.69M$44.34M$47.85M$51.81M$56.18M$60.21M$64.61M$69.06M
Goodwill———————$0
Intangibles$1.75B$1.78B$1.82B$1.85B$1.89B$1.92B$1.98B$2.02B
Total assets$2.73B$2.84B$2.80B$2.92B$2.60B$2.70B$2.85B$2.98B
Current liabilities$94.33M$83.54M$74.71M$79.67M$77.43M$70.64M$74.98M$76.92M
Total liabilities$277.04M$301.03M$302.79M$344.15M$361.07M$387.91M$433.94M$479.90M
Shareholders' equity$2.45B$2.54B$2.50B$2.58B$2.24B$2.31B$2.41B$2.50B
Shares outstanding44.75M44.67M41.13M40.33M36.16M36.05M35.30M33.89M
Cash flow statement
Operating cash flow-$74.74M-$80.73M-$86.99M-$63.78M-$63.24M-$76.97M-$95.01M-$93.49M
Capital expenditure$4.73M$432,000$503,000$94,000$384,000$369,000$62,000$303,000
Free cash flow-$79.47M-$81.16M-$87.49M-$63.88M-$63.63M-$77.33M-$95.07M-$93.79M
Investing cash flow$47.68M-$46.58M-$93.44M-$236.70M$66.67M$70.37M$14.61M-$546.11M
Financing cash flow$370,000——$423.32M$0$0$0$0
Depreciation & amortization$3.89M$4.11M$4.21M$4.32M$4.40M$4.59M$4.70M$4.86M
Stock-based compensation$14.11M$19.56M$16.79M$13.77M$14.14M$14.17M$16.21M$13.58M

Free plan shows the latest 8 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.